Pharmacologically directed design of leukemia therapy.

W. Plunkett; V. Heinemann; E. Estey; M. Keating

doi:10.1007/978-3-642-74643-7_111

Pharmacologically directed design of leukemia therapy.

W. Plunkett, V. Heinemann, E. Estey, M. Keating

Experimental Therapeutics

Research output: Contribution to journal › Review article › peer-review

6 Scopus citations

Abstract

The ability to accumulate and retain the active metabolite of Ara-C varies widely among patients. Our studies demonstrate a significant correlation between clinical response and the pharmacokinetics of Ara-CTP in leukemia cells during therapy. Knowledge of the cellular pharmacology of Ara-CTP has been used to optimize dose rates and to design combination treatment schedules. An understanding of the cellular pharmacodynamics of other drugs is likely to be a useful parameter for planning treatment protocols.

Original language	English (US)
Pages (from-to)	610-613
Number of pages	4
Journal	Haematology and blood transfusion
Volume	33
DOIs	https://doi.org/10.1007/978-3-642-74643-7_111
State	Published - 1990

Access to Document

10.1007/978-3-642-74643-7_111

Cite this

@article{e0e7345e97b5436cb971426d189b1cb6,

title = "Pharmacologically directed design of leukemia therapy.",

abstract = "The ability to accumulate and retain the active metabolite of Ara-C varies widely among patients. Our studies demonstrate a significant correlation between clinical response and the pharmacokinetics of Ara-CTP in leukemia cells during therapy. Knowledge of the cellular pharmacology of Ara-CTP has been used to optimize dose rates and to design combination treatment schedules. An understanding of the cellular pharmacodynamics of other drugs is likely to be a useful parameter for planning treatment protocols.",

author = "W. Plunkett and V. Heinemann and E. Estey and M. Keating",

year = "1990",

doi = "10.1007/978-3-642-74643-7_111",

language = "English (US)",

volume = "33",

pages = "610--613",

journal = "Haematology and blood transfusion",

issn = "0171-7111",

}

TY - JOUR

T1 - Pharmacologically directed design of leukemia therapy.

AU - Plunkett, W.

AU - Heinemann, V.

AU - Estey, E.

AU - Keating, M.

PY - 1990

Y1 - 1990

N2 - The ability to accumulate and retain the active metabolite of Ara-C varies widely among patients. Our studies demonstrate a significant correlation between clinical response and the pharmacokinetics of Ara-CTP in leukemia cells during therapy. Knowledge of the cellular pharmacology of Ara-CTP has been used to optimize dose rates and to design combination treatment schedules. An understanding of the cellular pharmacodynamics of other drugs is likely to be a useful parameter for planning treatment protocols.

AB - The ability to accumulate and retain the active metabolite of Ara-C varies widely among patients. Our studies demonstrate a significant correlation between clinical response and the pharmacokinetics of Ara-CTP in leukemia cells during therapy. Knowledge of the cellular pharmacology of Ara-CTP has been used to optimize dose rates and to design combination treatment schedules. An understanding of the cellular pharmacodynamics of other drugs is likely to be a useful parameter for planning treatment protocols.

UR - http://www.scopus.com/inward/record.url?scp=0025042047&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025042047&partnerID=8YFLogxK

U2 - 10.1007/978-3-642-74643-7_111

DO - 10.1007/978-3-642-74643-7_111

M3 - Review article

C2 - 2182451

AN - SCOPUS:0025042047

SN - 0171-7111

VL - 33

SP - 610

EP - 613

JO - Haematology and blood transfusion

JF - Haematology and blood transfusion

ER -

Pharmacologically directed design of leukemia therapy.

Abstract

Access to Document

Other files and links

Fingerprint

Cite this